Johnson & Johnson (NYSE:JNJ) shares, rose in value, with the stock price down by -0.07% to the previous day’s close as strong demand from buyers drove the stock to $152.39.
Actively observing the price movement in the last trading, the stock closed the session at $152.50. The value of beta (5-year monthly) was 0.53 whereas the PE ratio was 27.32 over 12-month period. Referring to stock’s 52-week performance, its high was $175.97, and the low was $144.95. On the whole, JNJ has fluctuated by -4.36% over the past month.
With the market capitalization of Johnson & Johnson currently standing at about $367.07 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 16, 2024. The company’s Forward Dividend Ratio is 4.76, with its dividend yield at 3.12%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $2.64, which is expected to increase to $2.84 for fiscal year $10.65 and then to about $11.02 by fiscal year 2025. Data indicates that the EPS growth is expected to be 7.40% in 2025, while the next year’s EPS growth is forecast to be 3.50%.
Analysts have estimated the company’s revenue for the quarter at $21.41 billion, with a low estimate of $21.11 billion and a high estimate of $21.8 billion. According to the average forecast, sales growth in current quarter could jump down -13.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $88.41 billion, representing an increase of 3.80% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that JNJ’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 5.81, with the price of JNJ currently trading nearly -3.24% and -3.73% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.62, while the 7-day volatility ratio is showing 1.50% which for the 30-day chart, stands at 1.28%. Furthermore, Johnson & Johnson (JNJ)’s beta value is 0.53, and its average true range (ATR) is 2.02.
A comparison of Johnson & Johnson (JNJ) with its peers suggests the former has fared considerably weaker in the market. JNJ showed an intraday change of -0.07% in last session, and over the past year, it shrunk by -3.85%%.
Data on historical trading for Johnson & Johnson (NYSE:JNJ) indicates that the trading volumes over the past 10 days have averaged 6.77 million and over the past 3 months, they’ve averaged 7.06 million. According to company’s latest data on outstanding shares, there are 2.41 billion shares outstanding.
Nearly 0.16% of Johnson & Johnson’s shares belong to company insiders and institutional investors own 71.51% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.84 million shares as on Mar 15, 2024, resulting in a short ratio of 2.19. According to the data, the short interest in Johnson & Johnson (JNJ) stood at 0.66% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 10.96 million. The stock has fallen by -2.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the JNJ stock heading into the next quarter.
